83 results about "Right heart ventricle" patented technology

Methods and systems for monitoring a heart failure or transplant rejection status of a patient including use of a device or system to collect intramyocardial electrogram (IMEG) signals from the patient at different times automatically when a detected activity level of the patient is below a preset threshold level for a predetermined amount of time, and use of a device or system to generate a status indicator value proportional to a combination of parameters extracted from at least a portion of the collected IMEG signals. Methods and systems can also include measuring time delay values between IMEG signals collected from different locations in the patient. The IMEG signals can be collected from the right ventricular septum and the right ventricular apex of the patient or from the right and left ventricular myocardium of the patient.

The disclosure provides methods and apparatus of left ventricular pacing including automated adjustment of a atrio-ventricular (AV) pacing delay interval and intrinsic AV nodal conduction testing. It includes—upon expiration or reset of a programmable AV Evaluation Interval (AVEI)—performing the following: temporarily increasing a paced AV interval and a sensed AV interval and testing for adequate AV conduction and measuring an intrinsic atrio-ventricular (PR) interval for a right ventricular (RV) chamber. Thus, in the event that the AV conduction test reveals a physiologically acceptable intrinsic PR interval then storing the physiologically acceptable PR interval in a memory structure (e.g., a median P-R from one or more cardiac cycles). In the event that the AV conduction test reveals an AV conduction block condition or if unacceptably long PR intervals are revealed then a pacing mode-switch to a bi-ventricular (Bi-V) pacing mode occurs and the magnitude of the AVEI is increased.

Methods and process for detection of myocardial ischemia involve detection and analysis of changes in electrical conduction velocity within the heart to monitor changes in the condition of the cardiac muscle and indicate possible ischemia. Conduction velocity slows considerably when oxygen supply to the heart is reduced. Analysis of electrical conduction velocity can be used to verify the occurrence of myocardial ischemia in a more reliable manner. Changes in conduction velocity may be monitored based on conduction time between electrodes positioned in the left and right ventricles of the heart. The electrodes may be endocardial or epicardial electrodes. In general, the techniques may involve launching a stimulation waveform at one electrode and sensing a local cardiac depolarization at another electrode to assess conduction time.

The present invention is a high resolution, multi-function, conformal electronics device generally having a flexible and stretchable, high-density electrode array, integrated with a catheter (e.g., balloon catheter) for mapping, ablating, pacing and sensing of cardia tissue associated with heart arrhythmias. The active sensing electrode array can acquire diagnostic information including electrical (e.g., electrograms), mechanical (e.g., strain measurements), impedance (e.g., resistance), metabolic (e.g., pH or NADH measurement) from the underlying heart tissue surface with which it is in contact. The electrode array may be designed to be of various sizes and shapes to conform to the targeted cardiac tissue architecture (e.g. atrial, ventricle, right ventricular outflow tract, coronary sinus, pulmonary veins, etc.) corresponding to the specific type of cardiac arrhythmia. The present invention can precisely locate the source of arrhythmia as described above and deliver therapy from the same electrode array. This is achieved using a capacitive sensing electrode array that can not only monitor but also deliver electrical stimulation.

The invention relates to a medical prosthesis, and in particular a heart valve substitute comprising a pliant tubular conduit mounted on a resilient annular frame and tethered to a non-perforating anchor within the right or left ventricle of the heart, wherein the pliant tubular conduit is a reciprocating mechanical member that is compressed by pressurized working fluid within the ventricle during systole.

An anchoring system and related methods are provided for treatment of dilated hearts and of functional valve regurgitation, the system comprising one or more self- expandable or manually expandable anchors and associated devices for fixating a valve splint within the heart. For example, a spade-shaped assembly may be configured to be deployed in a right ventricle of the heart and to stabilize a puncturing instrument to puncture the septum. Various puncturing instruments may also be part of the anchoring system, including one or more of a flexible needle having a multiplicity of slits disposedalong the length of the needle, a trocar catheter with a retractable head, and a catheter needle having a blunt introducer to protect nearby tissue within the heart during advancing a guidewire. A cutter catheter and puncture location catheter may also be part of the system and be used during treatment.

The invention relates to the technical field of medical instruments, in particular to an electromagnetic cardiac pulse assisting device. The electromagnetic cardiac pulse assisting device comprises an inner membrane, an outer membrane supporting body, two permanent magnets, electromagnets, a power source and a controller. The inner membrane covers the surface of the heart, and the outer membrane supporting body covers the outer side of the inner membrane. The two permanent magnets are fixed to the outer side of the inner membrane and correspond to the left ventricle and the right ventricle respectively. The two electromagnets are fixed to the inner side of the outer membrane supporting body and are opposite to the permanent magnets. The power source and the controller are used for supplying power to the electromagnets and adjusting the magnitude and the direction of current, so that the electromagnets can apply repulsive force or attractive force to the permanent magnets, and then the heart is driven to contract or relax. The device has the advantages of being capable of assisting the heart of the human body to beat, high in controllability, capable of improving the heart failure symptom and prolonging the service life of a patient, simple in structure, small and exquisite in size, capable of being implanted only through surgical operation, convenient to replace, low in manufacturing and using cost, long in service life and easy to accept by doctors and patients.

The invention relates to a phantom device for reproducing the fluid perfusion in a body, said device comprising a phantom organ that may be introduced into a scanner, said phantom organ comprising a housing in which are defined a plurality of fluid channels, suitably of differing cross-sectional areas; a feed tube arranged to supply liquid to a first end of all of said channels and means for collecting liquid from the other end of the channels. Alternatively or additionally, the device may comprise an element comprising a phantom heart through which fluid can flow, wherein the phantom heart comprises a first chamber representing a right atrium which is arranged to receive fluid from a fluid supply, a second chamber representing a right ventricle which receives fluid leaving said first chamber, a third chamber representing a left atrium which receives fluid leaving the second chamber and a fourth chamber representing left ventricle which receives fluid leaving the third chamber; and wherein a phantom thoracic system is interposed between the second chamber and the third chamber.

Uses of the device in quality control, validation or calibration of monitoring devices such as magnetic resonance (MR) or computerised tomography (CT) scanners, in teaching or training of machine operatives or for research purposes including for research into scanners, scanning techniques or reagents such as contrast agents used in such processes, form further aspects of the invention.

The invention discloses a heart nuclear magnetic resonance image key point detection method based on a convolutional neural network, and the method comprises the steps of constructing the convolutional neural network, efficiently detecting the regions of a plurality of key points through a pixel-by-pixel classifier, predicting the distances from pixels to the centers of the key points, and guaranteeing the precise prediction of the key points. The false positive rate of detection is reduced and the accuracy of key point detection is ensured by removing false detection key points, removing leftand right ventricular intersection points, which are not between the left ventricle and the right ventricle, in the fusion information graph and obtaining the local maximum value in the fusion information graph according to the local maximum value search method.

The present disclosure relates to devices and methods for cardiac pacing therapy. Disclosed herein are methods for His bundle cardiac pacing; cardiac leads and leadless cardiac pacemakers that enables pacing and sensing of the His bundle as well as the right atrium and right ventricle; and delivery sheaths for placing the cardiac lead or leadless cardiac pacemaker in the heart. The devices and methods disclosed increase the success at which His bundle pacing can be implemented.

The invention is directed to methods and devices for optimization of biventricular pacing in subjects suffering from heart failure. The invention provides for a method for selection of optimal parameters for permanent pacing, the method comprising: positioning one or more arrays of lead wires in the posterior pericardium of a subject, wherein the arrays are connected to a multiplexing switch, wherein the switch is connected to a computer processor and a biventricular pacemaker, from the computer processor, generating a randomized sequence of: (i) pacing sites (VPS), (ii) right ventricular-left ventricular delays (RLDs), (iii) heart rates (HR); (iv) atrioventricular delays (AVDs), (v) or any combination or permutation thereof; and determining cardiac output in real time, using aortic flow velocity, thereby allowing selection of optimal parameters for permanent pacing.

An ultrasound imaging system is for determining stroke volume and/or cardiac output. The imaging system may include a transducer unit for acquiring ultrasound data of a heart of a subject (or an input for receiving the acquired ultrasound data), and a controller. The controller is adapted to implement a two-step procedure, the first step being an initial assessment step, and the second being an imaging step having two possible modes depending upon the outcome of the assessment. In the initial assessment procedure, it is determined whether regurgitant ventricular flow is present. This is performed using Doppler processing techniques applied to an initial ultrasound data set. If regurgitant flow does not exist, stroke volume is determined using segmentation of 3D ultrasound image data to identify and measure the volume of the left or right ventricle at each of end systole and end-diastole, the difference between them giving a measure of stroke volume. If regurgitant flow does exist, stroke volume is determined using Doppler techniques applied to ultrasound data continuously collected throughout a cardiac cycle.

The invention provides a construction method and application of a DSC2 gene knockout mouse model, and particularly relates to application of the DSC2 gene knockout mouse model in preparation of a reagent and a medicine for preventing and treating right heart disease, monitoring right ventricular diastole and contraction, and preparing an apoptosis pathway regulation reagent and a medicine or preparing a fibrosis pathway regulation reagent and a medicine. A DSC2 deletion mutant mouse is constructed on the basis of a C57BL/6J mouse through a CRISPR-Cas9 technology, and the DSC2 knockout mouse can effectively induce right ventricular cardiomyopathy and can be used for a mouse model for right ventricular cardiomyopathy research; after the DSC2 gene is simply knocked out, along with the increase of the age of the mouse, the mouse has the expression of right ventricular cardiomyopathy such as right ventricular enlargement, right ventricular myocardial fibrosis and middle and advanced right ventricular heart failure, so that the mouse model can be used as an effective model in subsequent molecular mechanism research on the right ventricular cardiomyopathy.

A method and device for dynamic device based AV delay adjustment is provided. The method comprises electrodes that are configured to be located proximate to an atrial (A) site and a right ventricular (RV) site. The method utilizes one or more processors for detecting an atrial paced (Ap) event or atrial sensed (As) event, and measures an AV interval corresponding to an interval between the Ap event or the As event and a sensed ventricular (Vs) event. The AV interval is associated with a current heart rate (HR). The method automatically dynamically adjusts a first AV delay based directly on the measured AV interval, identifies a scale factor associated with the current HR, calculates a second AV delay by scaling the first AV delay based on the scale factor and manages a pacing therapy, utilized by the IMD, based on the first and second AV delays.

The invention provides an artificial heart valve. The length of the anterior and posterior valve grasping lugs is greater than that of the septal valve grasping lugs, so that the anterior and posterior valve grasping lugs and the septal valve grasping lugs are designed differently to adapt to different anatomical structures; the partition valve grabbing lug is used for being anchored on a partition valve of the tricuspid valve leaflet, the anterior and posterior valve grabbing lug is used for being anchored on an anterior valve and/or posterior valve of the tricuspid valve leaflet, so that the tricuspid valve leaflet is clamped between the flange section and the grabbing lug section, and the flange section and the grabbing lug section structure of the outer-layer support have an enough axial anchoring force; the axial anchoring of the artificial heart valve can be achieved without additionally arranging a needling structure, damage to native tissue is small, and the artificial heart valve can be stably anchored between the right atrium and the right ventricle without a large main body section diameter.

The invention relates to the field of medical simulation teaching appliances, in particular to a modular cardiac pulse simulation device and a biological simulation esophagus ultrasonic simulation system. The modular heart pulsation simulation device comprises a simulated heart, a left heart pulsation simulation unit and a right heart pulsation simulation unit, the simulated heart is arranged in the ultrasonic operation unit; the left heart pulsation simulation unit comprises an aorta compliance module, an aorta damping module and a left atrial fluid volume module which are sequentially communicated, and further comprises a left ventricular pulsation driving module. And/or the right heart pulsation simulation unit comprises a pulmonary artery compliance module, a pulmonary artery damping module and a right atrial fluid volume module which are communicated in sequence, and further comprises a right ventricular pulsation driving module. According to the device, the actual human physiological pulsating flow effect can be simulated in a highly bionic manner, the modular design can meet the application of various scenes, and doctors can be effectively trained to carry out heart diseasediagnosis and treatment.